

PRESS RELEASE



August 9, 2018, Lund, Sweden

Invitation to Immunovia's telephone conference on Thursday, the 9th of August, 2018 at 15:00 (CET)

Due to today's announcement of the non-small cell lung cancer (NSCLC) collaborative study with a major global pharma company, Immunovia invites to a telephone conference today on August 9, at 15:00 (CET). The presentation will be held in English. After a short presentation by CEO Mats Grahn, you will have an opportunity to ask questions. Please dial in a few minutes before the presentation begins.

Date: August 9, 2018

Time: 15:00 (CET)

Participant dial in numbers

SE: +46856642662

BE: +3224040635

CH: +41225675548

DE: +4969222229046

DK: +4582333178

FR: +33170750712

NE: +31207168416

NO: +4723500254

UK: +442030089803

US: +16465025116

For questions as well as for timing of interviews:

ir@immunovia.com

On the Immunovia website under Investors/Audio Gallery (<https://immunovia.com/investors/audio-gallery/>) there will be an MP3 file for those who want to listen to the conference call later, the file is available within two hours of the end of the conference call.

For more information, please contact:

Mats Grahn

Chief Executive Officer, CEO, Immunovia

Tel.: +46-70-5320230

Email: mats.grahn@immunovia.com

About Immunovia

Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia's core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.

###